Molecular Partners Advances Phase 2 Trial for Cholangiocarcinoma Treatment
Event summary
- Molecular Partners' Phase 2 TACTIC trial for MP0317 in cholangiocarcinoma is actively recruiting patients across nine sites.
- The randomized study aims to enroll 75 patients, with data expected in 2027 and completion by 2028.
- MP0317 is being tested in combination with durvalumab and gemcitabine-cisplatin chemotherapy as a first-line treatment.
- A trial-in-progress poster will be presented at ESMO 2026 in October.
The big picture
Molecular Partners' progress in the Phase 2 TACTIC trial underscores the growing focus on combination therapies in oncology. The study's design, targeting the tumor microenvironment with MP0317 alongside standard-of-care treatments, reflects broader industry trends toward personalized and immune-modulating cancer therapies. Success here could validate Molecular Partners' DARPin platform as a key innovation in treating aggressive cancers like cholangiocarcinoma.
What we're watching
- Clinical Efficacy
- How MP0317's combination therapy will impact progression-free survival rates in cholangiocarcinoma patients.
- Regulatory Pathway
- The pace at which Molecular Partners can advance MP0317 through subsequent clinical phases based on Phase 2 results.
- Market Differentiation
- Whether MP0317's unique mechanism of action will position it as a competitive option in the cholangiocarcinoma treatment landscape.
Related topics